Since the 1970s , the categories of transdermal medications has been addressed include:
· Local anesthesia
· Angina pectoris
· Motion sickness
· Smoking control
· Major depression
· Parkinson disease
· Alzheimer disease
· Attention deficit hyperactivity disorder (ADHD)
Till now, many macromolecular biomedicines which have low bioavailability, rapid metabolism, poor absorption, first-pass effect, and serious adverse effects require transdermal administration to alter the oral administration in the clinical, particularly in inflammatory diseases, gastric ulcer, diabetes, heart failure, and cancer, etc. Due to the limitations of transdermal drug delivery (low drug loading and release efficiency, inferior durability, and short curative period), the number of transdermal drugs approved in the USA and EU is fewer than 50. Many drugs that could be potentially delivered via the skin have not been explored yet.
So our product BanGel could be a promising application to deliver such therapeutic drugs through transdermal routes.